<DOC>
	<DOCNO>NCT02928445</DOCNO>
	<brief_summary>This 6-month extension study provide information regard long-term safety tolerability intepirdine ( RVT-101 ) subject Dementia Lewy body ( DLB ) participate double-blind , placebo-controlled , lead-in study RVT-101-2001 .</brief_summary>
	<brief_title>Long-Term Extension Study Intepirdine ( RVT-101 ) Subjects With Dementia With Lewy Bodies : HEADWAY-DLB Extension</brief_title>
	<detailed_description>This 6-month , double-blind , extension study provide information regard long-term safety tolerability intepirdine ( RVT-101 ) subject DLB participate double-blind , placebo-controlled , lead-in study RVT-101-2001 . Subjects randomize RVT-101 35-mg RVT-101 70-mg treatment group lead-in study RVT-101-2001 remain treatment group study ; subject randomize placebo treatment group lead-in study assign RVT-101 70-mg treatment group study . Various background therapy , include acetylcholinesterase inhibitor memantine , allow .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<criteria>Participated leadin study RVT1012001 . Any clinically relevant concomitant disease , , opinion Investigator , make subject unsuitable inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dementia Lewy body</keyword>
	<keyword>dementia</keyword>
	<keyword>RVT-101</keyword>
	<keyword>intepirdine</keyword>
	<keyword>Lewy body</keyword>
</DOC>